Use of TheraSphere® Yttrium-90 Glass Microspheres for Primary and Metastatic Liver Tumor
Learn More About This Topic: Chat with Us | Email Us
Phase I/II, Use of TheraSphere® Yttrium-90 Glass Microspheres for Primary and Metastatic Liver Tumor
Summary
This study is being conducted to provide supervised access to treatment with TheraSphere® to eligible patients with primary and metastatic cancer to the liver. It is also being offered to evaluate patient experience and toxicities associated with TheraSphere® treatment. In adddition, the study will evaluate predisposing factors that may influence results and toxicity.
For More Information:
Please contact one of our Oncology Information Specialists at 1-800-615-3055 to learn more about this clinical trial. Oncology Information Specialists are available 24 hours a day, 7 days a week, 365 days a year.
